Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines

Anticancer Research

Volumn 17, Issue 6 D, 1997, Pages 4419-4425

  Hoffmann, Thomas ^a   Hafner, Dieter ^a   Ballo, Hilmar ^a   Haas, Inge ^a   Bier, Henning ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Cisplatin; Epidermal growth factor receptor; Head and neck cancer; Monoclonal antibodies

Indexed keywords

CISPLATIN; EMD 55900; EPIDERMAL GROWTH FACTOR RECEPTOR; ICR 62; MONOCLONAL ANTIBODY; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; COLORIMETRY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CELL LINE; CELL SURVIVAL; CISPLATIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEAD AND NECK NEOPLASMS; HUMANS; MICE; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR CELLS, CULTURED;

EID: 0031427295     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Cohen S, Fava R, Sawyer ST: Purification and characterization of epidermal growth factor receptor protein kinase from mouse liver. Proc Natl Acad Sci 79: 6237-6241, 1982.
2. Ullrich A, Coussens L, Hayflick JS, Dull T, Gray A, Tam A, Lee L, Yarder Y, Liebermann T, Schlessinger JM, Downward J, Mayes E, Whittle N, Waterfield M, Seeburg P: Human epidermal growth factor receptor cDNA sequence and aberant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309: 418-425, 1984.
3. Sporn MB, Roberts AB: Peptide growth factors and their receptors. Springer, Berlin Heidelberg New York, 1991.
4. Aaronson SA: Growth factors and cancer. Science 254: 1146-1152, 1991.
5. Schlessinger J, Ullrich A: Growth factor signaling by receptor tyrosine kinases. Cell 9: 383-388, 1992.
6. Cowley GP, Smith JA, Gusterson BA: Increased EGF receptors on human squamous carcinoma cell lines. Br J Cancer 53: 223-229, 1986.
7. Ozanne B, Richards C.S, Hendler F, Burns D, Gusterson B: Overexpression of the EGF receptor is a hallmark of squamous cell carcinomas. J Pathology 149: 9-14, 1986.
8. Partridge M, Gullick WJ, Langdon JD, Sheriff M: Expression of epidermal growth receptor on oral squamous cell carcinomas. Br J Oral Max Fac Surg 26: 381-386, 1988.
9. Bergler W, Bier H, Ganzer U: The expression of epidermal growth factor receptors in the oral mucosa of patients with oral cancer. Arch Otorhinolaryngol 246: 121-125, 1989.
10. Khazaie K, Schirmacher V, Lichtner RB: EGF receptor in neoplasia and metastasis. Cancer Metast Rev 12: 255-274, 1993.
11. Dassonville O, Formento JL, Francoual M, Ramaioli A, Santini J, Schneider M, Demard F, Milano G: Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 11: 1873-1878, 1993.
12. Christensen ME, Engbaek F, Therkildsen MH, Bretlau P, Nexo E: A sensitive enzyme-linked immunosorbent assay used for quantitation of epidermal growth factor receptor protein in head and neck carcinomas: evaluation, interpretations and limitations. Br J Cancer 72: 1487-1493, 1995.
13. Bier H, Reiffen KA, Haas I, Stasiecki P: Dose-dependent access of murine anti-epidermal growth factor receptor monoclonal antibody to tumor cells in patients with advanced laryngeal and hypopharyngeal carclnoma. Eur Arch Otorhinolaryngol 252: 433-439, 1995.
14. Bier H, Hoffmann T: Epidermal growth factor receptor in head and neck squamous cell carcinomas. In: Werner JA, Lippert BM, Rudert HH (eds.): Head and Neck Cancer - Advances in Basic Research, Excerpta Medica Int. Congress Series 1114: 225-234, 1996.
15. Partridge M, Green MR, Langdon JD, Feldmann M: Production of TGF alpha and TGF beta by cultured keratinocytes, skin and oral squamous cell carcinomas - potential autocrine regulation of normal and malignant epithelial cell proliferation. Br J Cancer 60: 542-548, 1989.
16. Christensen ME, Therkildsen MH, Poulsen SS, Bretlau P: Transforming growth factor alpha and epidermal growth factor in laryngeal carcinomas demonstrated by immunohistochemistry. ActaOtolaryngol 113: 563-567, 1993.
17. Sporn MB, Todaro GJ: Autocrine secretion and malignant transformation of cells. New Engl J Med 303: 878-880, 1980.
18. Di Marco E, Pierce JH, Fleming TP, Kraus MH, Molloy CJ, Aaronson SA, Di Fore PP: Autocrine interaction between TGFalpha and the EGF-receptor: quantitative requirements for induction of the malignant phenotype. Oncogene 4: 831-838, 1989.
19. Mendelsohn J: The epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. Semin Cancer Biol 1: 339-344, 1990.
20. Modjtahedi H, Dean C: The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer. Int J Oncol 4: 277-296, 1994.
21. Schreiber AB, Lasx I, Yarden Y, Eshhar Z, Schlessinger J: Monoclonal antibodies against receptor for epidermal growth factor induce early and delayed effects of epidermal growth factor. Proc Natl Acad Sci 78: 7535-7539, 1981.
22. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato JH: Biological effects in vitro of MAbs to human EGF receptors. Mol Biol Med 1: 511-514, 1983.
23. Murthy U, Basu A, Rodeck U, Herlyn M, Ross AH, Das M: Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide. Arch Biochem Biophys 225: 549-569, 1987.
24. Modjtahedi H, Styles JM, Dean C: The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468. Br J Cancer 67: 247-253, 1993.
25. Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J: Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 44: 1002-1007, 1984.
26. Rodeck U, Herlyn M, Herlyn D, Molthoff C, Atkinson B, Varello M, Steplewski Z, Koprowski H: Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: immunological mediated and effector cell-independent effects. Cancer Res 47: 3692-3696, 1987.
27. Modjtahedi H, Eccles S, Sandle J, Box G, Titley J, Dean C: Differentiation or immune destruction: Two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor. Cancer Res 54: 1695-1701, 1994.
28. Sturgis EM, Sacks PG, Masui H, Mendelsohn J, Schantz SP: Effects of antiepidermal growth factor receptor antibody 528 on the proliferation and differentiation of head and neck cancer. Otolaryngol Head Neck Surg 111: 633-643, 1994.
29. Carey TE: Establishment of epidermoid carcinoma cell lines. In: RE Wittes (ed.): Head and Neck Cancer. Wiley, London, pp 287-314, 1985.
30. Carey TE: Head and neck tumor cell lines. In: RJ Hay (ed.): Atlas of human tumor cell lines. Academic Press, San Diego, pp 79-120, 1994.
31. Zenner HP, Lehner W, Herrmann IF: Establishment of carcinoma cell lines from the larynx and submandibular gland. Arch Otolaryngol 225: 269-277, 1979.
32. Bier H, Bergler W, Mickisch G, Wesch H and Ganzer U: Establishment and characterization of cisplatin-resistant sublines of the human squamous carcinoma cell line HLac 79. Acta Otolaryngol 110: 466-473, 1990.
33. Fabricant R, DeLarco JE, Todara GJ: Nerve growth factor receptors on human melanoma cells in culture. Proc Natl Acad Sci 74: 565-569, 1977.
34. Mayes ELV, Waterfield MD: Biosynthesis of the epidermal growth factor receptor in A431 cells. The EMBO J 3: 531-537, 1984.
35. Bier H, Hoffmann T, Eikelmann P, Hafner D: Chemosensitivity of head and neck squamous carcinoma cell lines is not primarily correlated with glutathione level but is modified by glutathione depletion. J Cancer Res Clin Oncol 122: 653-658, 1996.
36. Carmichael J, de Graff WG, Gazdar AF, Minna JD, Mitchell JB: Evaluation of a Tetrazolium-based semiautomatic assay: assessment of chemosensitivity testing. Cancer Res 47: 936-942, 1987.
37. Hafner D, Heinen E, Noack E: Mathematical analysis of concentration-response-relationships: a method for the evaluation of the ED50 and the number of receptor binding sites using a logit transformation. Drug Res 27: 1871-1873, (1977)
38. Poch G, Holzmann S: Quantitative estimation of overadditive and underadditive drug effects by means of theoretical, additive dose response curves. J Pharmacol Meth 4: 179-188 (1980)
39. Prime SS, Game SM, Matthews JB, Stone A, Donelly MJ, Yeudall WA, Patel V, Sposto R, Silverthorne A, Scully C: Epidermal growth factor and transforming growth factor alpha characteristics of human oral carcinoma cell lines. Br J Cancer 69: 8-15, 1994.
40. Stanton P, Richards S, Reeves J, Nikolic M, Edington K, Clark L, Robertson G, Souter D, Mitchell R, Hendler FJ, Cooke T, Parkinson EK, Ozanne BW: Epidermal growth factor receptor expression by human squamous cell carcinomas of the head and neck, cell lines and xenografts. Br J Cancer 70: 427-433, 1994.
41. Atlas I, Mendelsohn J, Baselga J, Fair WR, Masui H, Kumar R: Growth regulation of human renal carcinoma cells: role of transforming growth factor alpha. Cancer Res 52: 3335-3339, 1992.
42. Carpenter G: Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem 56: 881-914, 1987.
43. Derynck R, Goeddel DV, Ullrich A, Guttermann JU, Williams RD, Bringman TS, Berger WH: Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res 47: 707-712, 1987.
44. Brachmann R, Lindquist PB, Nagashima M: Transmembrane TGF alpha precursors activate EGF/TGF alpha receptors. Cell 56: 691-700, 1989.
45. Baselga J, Mendelsohn J, Kim YM, Pandiella A: Autocrine regulation of membrane transforming growth factor-alpha cleavage. JBiol Chem 277: 3279-3284, 1996.
46. Fan Z, Baselga J, Masui H, Mendelsohn J: Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis diamminedichloroplatinum on well established A431 cell xenografts. CancerRes 53: 4637-4642, 1993
47. Modjtahedi H, Dean C: Antibody-induced inhibition of growth of EGFR overexpressing tumours occurs in the absence of receptor down-regulation. Int J Oncol 7: 783-788, 1995.
48. Rodeck U, Williams N, Murthy U, Herlyn M: Monoclonal antibody 425 inhibits growth stimulation of carcinoma cells by exogenous EGF and tumor-derived EGF/TGF alpha. J Cell Biochem 44: 69-79, 1990.
49. Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J: Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Investig 95: 1897-1905, 1995.
50. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456-1462, 1995.
51. Mendelsohn J, Baselga J, Wu X, Peng D, Brown C, Chou JL, Masui H, Fan Z: EGF Receptor inhibition by antibody as anticancer therapy. In: Lichtner RB, Harkins RN (eds.): EGF Receptor in Tumor Growth and Progression, Springer, Berlin, Ernst Schering Research Foundation Workshop 19, pp 233-251, 1997.
52. Hickman JA: Apoptosis induced by anticancer drugs. Cancer Metast Rev 11: 121-139, 1992.
53. Barry MA, Behnke CA, Eastman A: Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 40: 2353-2362, 1990.
54. Amagase H, Kakimoto M, Hashimoto K, Fuwa T, Tsukagoshi S: Epidermal growth factor receptor-mediated selective cytotoxicity of antitumor agents toward human xenografts and murine syngeneic solid tumors. Jpn J Cancer Res 80: 670-678, 1989.
55. Christen RD, Hom DK, Porter Andrews PA, MacLeod CL, Hafstrom L, Howell SB: Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J Clin Invest 86: 1632-1640, 1990.
56. Basu A, Evans RW: Comparism of effects of growth factors and protein kinase C activators on cellular sensitivity to cis-diamminedichloroplatinum (II). Int J Cancer 58: 587-591, 1994.
57. Kroning R, Jones JA, Hom DK, Chuang CC, Sanga R, Los G, Howell SB, Christen RD: Enhancement of drug sensitivity of human malignancies by epidermal growth factor. Br J Cancer 72: 615-619, 1995.
58. Hofmann J, Doppler W, Jakob A, Maly K, Posch L, Uberall F, Grunicke HH: Enhancement of the antiproliferative effect of cis-diamminedichloroplatinum (II) and nitrogen mustard by inhibitors of protein kinase C. Int J Cancer 42: 382-388, 1988.
59. Modjtahedi H, Hickish T, Nicolson M, Moore J, Styles J, Eccles S, Jackson E, Salter J, Sloane J, Spencer L, Priest K, Smith I, Dean C, Gore M: Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR 62 in head and neck or lung cancer. Br J Cancer 73: 228-235 (1996)